EPIRUS Biopharma (EPRS) Tops Q4 EPS by 19c
Tweet
Share
E-mailGet Alerts EPRS Hot Sheet
Join SI Premium – FREE
EPIRUS Biopharma (NASDAQ: EPRS) reported Q4 EPS of ($0.80), $0.19 better than the analyst estimate of ($0.99).
For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
